Key Takeaways
A subcutaneous implant delivering semaglutide could solve the adherence problem plaguing the GLP-1 weight-loss market.
Vivani Medical is developing a tiny implant placed under the skin that releases semaglutide over months, targeting the single biggest obstacle in the booming GLP-1 market: keeping patients on treatment long enough to sustain weight loss. The biotech company's experimental device contains the same active ingredient used in Novo Nordisk's Wegovy and Ozempic, which together have driven GLP-1 use to a record 11% of US adults — roughly 40 million people, according to a Gallup survey published July 7.
"Adherence is the hidden bottleneck in obesity pharmacotherapy," said Sam Goldstein, a biotech analyst who covers metabolic disease. "Patients who stop GLP-1 therapy within the first year typically regain two-thirds of the weight they lost. An implant that eliminates weekly injections could fundamentally change the compliance curve."
The implant is in early-stage development, Vivani said, with no clinical trial dates disclosed. It would deliver semaglutide continuously from a reservoir roughly the size of a grain of rice, bypassing the need for patients to self-administer weekly injections. The approach mirrors a broader industry push to improve GLP-1 persistence: Medicare launched a temporary GLP-1 Bridge program on July 1 that caps monthly copayments at $50 for eligible Part D enrollees through the end of 2027, covering drugs including Wegovy and Eli Lilly's Zepbound KwikPen.
The adherence problem carries enormous financial consequences. Analysts project the global GLP-1 market could exceed $100 billion annually by 2030, but that forecast depends on patients staying on therapy. Clinical data shows patients lose an average of 15% to 20% of body weight on GLP-1s when combined with diet and exercise, yet real-world persistence rates tell a different story. A 2024 analysis found that fewer than 40% of patients prescribed GLP-1s for weight loss remained on treatment after 12 months, with side effects, cost, and injection fatigue cited as the top reasons for discontinuation.
Vivani's implant technology, if successful, would eliminate the injection burden entirely. The company has not disclosed the implant's duration of effect, but similar subcutaneous drug delivery platforms for other indications have demonstrated six-month to 12-month release profiles. The device would need to match the efficacy of weekly injections — where semaglutide at the 2.4 mg maintenance dose produces a mean weight reduction of 14.9% at 68 weeks, per Novo Nordisk's STEP 1 trial — while maintaining a comparable safety profile.
Vivani enters a field dominated by Novo Nordisk and Eli Lilly, which together control the vast majority of the GLP-1 market. Novo's Wegovy generated $8.5 billion in 2025 revenue, while Lilly's Zepbound brought in $5.3 billion. Both companies rely on injectable formulations, though each has oral candidates in development: Novo's oral semaglutide (Rybelsus) is approved for diabetes at lower doses, and Lilly's orforglipron is in Phase 3 for weight loss.
An implant delivery system would differentiate Vivani from both the injectable and oral approaches. The company's cash position and development timeline remain key questions for investors. Vivani has not disclosed its cash runway or projected trial start date, though preclinical data would be the next milestone.
The broader GLP-1 adherence challenge has attracted other innovators. A separate effort by a consortium of academic medical centers is testing a once-monthly injectable formulation of semaglutide, while several device companies are developing smart auto-injectors that track patient compliance. Vivani's implant represents the most ambitious departure from the current standard of care — but also carries the longest path to market, requiring Phase 1 through Phase 3 trials and FDA approval.
For investors, the thesis hinges on execution. If Vivani can demonstrate a six-month or longer release profile with safety comparable to weekly semaglutide, the implant could capture a meaningful share of the adherence-constrained segment of the GLP-1 market. The US adult obesity rate has already fallen from a 2022 peak of 39.9% to 36.4% in 2026, according to Gallup, suggesting the drugs are working — but the question is whether patients will stay on them long enough to make the decline durable.
This article is for informational purposes only and does not constitute investment advice.
